Prostate Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Blue Earth Diagnostics

 Breaking News
  • No posts were found

Prostate Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Blue Earth Diagnostics

December 05
20:32 2023
Prostate Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Blue Earth Diagnostics

DelveInsight’s, “Prostate Cancer Pipeline Insight 2023” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in the Prostate Cancer pipeline landscape. It covers the Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Prostate Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Prostate Cancer Pipeline Report

  • DelveInsight’s Prostate Cancer pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for Prostate Cancer treatment.
  • The leading companies working in the Prostate Cancer Market include Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Blue Earth Diagnostics, Advaxis, Inc., Emtora Biosciences, Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc., Arvinas Inc., Epizyme, Harpoon Therapeutics, Plexxikon, Regeneron Pharmaceuticals, Veru Inc., Jiangsu Hengrui Medicine Co., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Genovax, Cancer Targeted Technology, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Allife Medical Science and Technology, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., and others.
  • Promising Prostate Cancer Pipeline Therapies in the various stages of development include Capivasertib, Enzalutamide, Abiraterone, rosuvastatin, digoxin, 18F-PSMA-1007, rhPSMA-7.3 (18F) Injection, and others.
  • December 2023: Amunix, a Sanofi Company announced a study of Phase 1 & 2 clinical trials for AMX-500 (SAR446329). The study will be conducted in 4 parts and will commence with dose escalation of AMX-500 as a monotherapy (Part 1), followed by monotherapy dose expansion (Part 2).
  • November 2023: AstraZeneca announced a study of Phase 3 clinical trials for abiraterone acetate. The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.
  • April 2023: Surface Oncology announced a study of phase 2 clinical trails for SRF617, etrumadenant, and zimberelimab. This trial will look at the safety and preliminary efficacy of SRF617 in combination with etrumadenant and zimberelimab in patients with metastatic castration-resistant prostate cancer (mCRPC).
  • August 2023: AstraZeneca announced a study of phase 3 clinical trials for olaparib and abiraterone acetate. The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.

 

Request a sample and discover the recent advances in Prostate Cancer Treatment Drugs @ Prostate Cancer Infection Pipeline Outlook Report

 

In the Prostate Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Prostate Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Prostate Cancer Overview

The prostate is a small walnut shaped gland in the pelvis of men. It is located next to the bladder and can be examined by getting a digital rectal exam. Prostate Cancer is a form of cancer that develops in the prostate gland. It is the second-leading cause of cancer deaths for men in the U.S.

 

Find out more about Prostate Cancer Treatment Landscape @ Drugs for Prostate Cancer Treatment

 

Prostate Cancer Emerging Drugs Profile

  • Pembrolizumab: Merck & Co
  • Talazoparib: Pfizer
  • ODM-208: Orion
  • ZEN 3694: Zenith Epigenetics
  • EPI-7386: ESSA Pharma

 

Prostate Cancer Pipeline Therapeutics Assessment

There are approx. 200+ key companies which are developing the Prostate Cancer therapies. The Prostate Cancer companies which have their Prostate Cancer drug candidates in the most advanced stage, i.e. phase III include, Merck & Co.

 

DelveInsight’s Prostate Cancer pipeline report covers around 200+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

 

Prostate Cancer Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Learn more about the emerging Prostate Cancer Pipeline Therapies @ Prostate Cancer Clinical Trials Assessment

 

Scope of the Prostate Cancer Pipeline Report

  • Coverage- Global
  • Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Prostate Cancer Companies- Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Blue Earth Diagnostics, Advaxis, Inc., Emtora Biosciences, Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc., Arvinas Inc., Epizyme, Harpoon Therapeutics, Plexxikon, Regeneron Pharmaceuticals, Veru Inc., Jiangsu Hengrui Medicine Co., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Genovax, Cancer Targeted Technology, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Allife Medical Science and Technology, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., and others.
  • Prostate Cancer Pipeline Therapies- Capivasertib, Enzalutamide, Abiraterone, rosuvastatin, digoxin, 18F-PSMA-1007, rhPSMA-7.3 (18F) Injection, and others.

 

Dive deep into rich insights for new drugs for Prostate Cancer treatment, Visit @ Prostate Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Prostate Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Pembrolizumab: Merck & Co
  8. Drug profiles in the detailed report….
  9. Mid Stage Products (Phase II)
  10. ODM-208: Orion Pharma
  11. Drug profiles in the detailed report….
  12. Early Stage Products (Phase I)
  13. EPI 7386: ESSA Pharma
  14. Drug profiles in the detailed report….
  15. Preclinical and Discovery Products
  16. Drug name: Company name
  17. Drug profiles in the detailed report…
  18. Inactive Products
  19. Prostate Cancer Key Companies
  20. Prostate Cancer Key Products
  21. Prostate Cancer- Unmet Needs
  22. Prostate Cancer- Market Drivers and Barriers
  23. Prostate Cancer- Future Perspectives and Conclusion
  24. Prostate Cancer Analyst Views
  25. Prostate Cancer Key Companies
  26. Appendix

 

For further information on the Prostate Cancer pipeline therapeutics, reach out to Prostate Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/familial-lipoprotein-lipase-deficiency-market

Related Articles

Categories